Copaxone is the brand name for glatiramer acetate, an injectable medicine for relapsing forms of multiple sclerosis (MS). Its path from laboratory research to treatment began with Weizmann Institute scientists Michael Sela, Ruth Arnon and Dvora Teitelbaum; Teva licensed and developed the compound, and the U.S. Food and Drug Administration (FDA) lists 1996 as its initial U.S. approval.
From a Weizmann discovery to a licensed product
Glatiramer acetate is a synthetic mixture of amino-acid polymers studied by the three Weizmann researchers. Yeda, the Institute’s technology-transfer company, licenses research inventions to industry. Its account of research commercialization identifies Yeda’s role in licensing Weizmann discoveries; Weizmann’s institutional history records the research and the resulting treatment.
Licensing allowed a pharmaceutical company to take the research into product development, clinical evaluation and regulatory review. Those stages turn a laboratory finding into a medicine that can be produced consistently and prescribed for a defined indication.
What FDA approval covers
The FDA’s prescribing information identifies Copaxone as glatiramer acetate injection and gives the initial U.S. approval year as 1996. The 2019 label indicates it for treatment of relapsing forms of MS in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The FDA label also specifies subcutaneous administration.
The label establishes the approved uses and dosing information; it does not describe the medicine as a cure. Copaxone is one example of Israeli academic research reaching patients through a commercial license and pharmaceutical development. A separate university-industry path produced the Parkinson’s medicine Azilect.